1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"European Partnership on Rare Diseases (ERDERA) (Phase 2)" is currently closed and not accepting applications.
European Partnership on Rare Diseases (ERDERA) (Phase 2) is sponsored by European Commission — Horizon Europe. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The EU is reinforced as an internationally recognised driver of research and innovation in Rare Diseases (RD) and thereby substantially contributing to the achievement of the Sustainable Development Goals related to rare diseases. Research funders align, adopt and implement their RD research policies allowing for the optimal generation and translation of knowledge into meaningful health products and interventions responding to the needs of people living with a rare disease across Europe and globally. The RD research community at large benefit from and use an improved comprehensive knowledge framework and cross-border FAIR [1] data access and analysis, including rare diseases registries, by integrating the EU, national/regional data and information infrastructures to improve translational research. People living with a rare disease, including those from underrepresented communities, benefit from a more timely, equitable access to innovative, sustainable and high-quality healthcare including novel diagnosis and treatments, taking stock of highly integrated research and healthcare systems. Researchers, innovators -as well as people living with a rare disease and their advocates (as co-creators)- effectively constitute and operate into an integrated research and innovation ecosystem to deliver cost-effective diagnosis and treatments. Public and private actors, including civil society (e.g. Non-Governmental Organisations, charities), establish coordinated and efficient multi-stakeholder collaborations at EU and national (including regional) levels, allowing for more effective clinical research, for example aiming at improved success rates of therapeutic development. Scope: This topic targets an action under Article 24(2) HE Regulation aiming to add additional activities to existing grant agreements, together with additional partners (if relevant) that would deliver on those activities. The award of a grant to continue the partnership in accordance with this call should be based on a proposal submitted by the coordinator of the consortium funded under topic HORIZON-HLTH-2023-DISEASE-07-01: “European Partnership on Rare Diseases” and the additional activities (which may include additional partners) to be funded by the grant should be subject to an evaluation. Taking into account that the present action is a continuation of the topic HORIZON-HLTH-2023-DISEASE-07-01: “European Partnership on Rare Diseases” and foresees an amendment to an existing grant agreement, the proposal should present the additional activities (including additional partners) to be covered by the award primarily in terms of grant agreement revisions. The existing action, the “European Rare Diseases Research Alliance” (ERDERA) can only reasonably be enhanced and enlarged on the basis of the existing consortium [2] , as the co-funded framework established cannot simply be replaced without significant disruption, given the top-quality, long-term expertise and wide coverage of the beneficiaries comprising this consortium. The proposal should thus present the specific additional activities (including, if relevant, additional partners) foreseen for the second instalment of the partnership. The partnership should continue to contribute to priorities of the communication “On effective, accessible and resilient health systems” (COM(2014) 215 final) [3] , the “Communication from the Commission on enabling the digital transformation of health and care in the Digital Single Market; empowering citizens and building a healthier society” (COM(2018) 233 final) [4] , the "Council conclusions on the Future of the European Health U
Programme areas: Health Care Systems, Non-Communicable and Rare Diseases, Tools, Technologies and Digital Solutions for Health and Care, including personalised medicine, Health throughout the Life Course, Infectious Diseases, including poverty-related and neglected diseases, Health, Global Challenges and European Industrial Competitiveness, Horizon Europe (HORIZON)
Keywords: Anticancer therapy, Biobanks, Biomarkers, Cancer and its biological basis, Cardiac and Cardiovascular systems, Child health, Chronic diseases, Clinical data, Clinical information, Clinical management, Clinical medicine, Clinical neurology, Clinical research, Clinical targets, Clinical trials, Cohort studies, Collective Awareness Platforms, Comparative effectiveness research, Congenital heart disease, Degenerative diseases, Dermatology and venereal diseases, Electronic patient files, Endocrinology, Endocrinology and metabolism (including diabetes, hormones), Epidemiology, Ethics in medical sciences, Gene therapy, cell therapy, regenerative medicine, General and internal medicine, Genomics, comparative genomics, functional genomics, Global health, Haematology, Health care, Health care sciences and services (including hospital administration, health care financing), Health data, Health management systems, Health policies, Health policy and services, Health sciences, Health services, health care research, Health-related biotechnology, Healthcare system, Human genetics, Immunology, Integrated care, Interventional clinical trials, Medical biotechnology, Medical biotechnology related ethics, Medical statistics, Meta-analysis, Metabolism, biological basis of metabolism related disorders, Nephropathy, Neurodegenerative disorders, Neurological disorders (e.g. Alzheimer's disease, Huntington's disease, Parkinson's disease), Neuropathy, Neurosciences (including psychophysiology), Non-communicable diseases (except for neural/psychiatric and immunity-related), Oncology, Ophthalmology, Other clinical medicine subjects, Otorhinolaryngology, Paediatrics, Patient care, Patient stratification, Pediatric cardiology, Personalised medicine, Public health, Quality of health care, Quality-of-life, Rare diseases, Registries, Research integrity and research misconduct, Respiratory systems, Risk factors, Social biomedical sciences (includes family planning, sexual health, psycho-oncology, political and social effects of biomedical research), Social structure, inequalities, social mobility, interethnic relations, Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions (pharmacogenomics, gene-based, Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction), Tissue banks, Translational medicine, Transplantation, Urology and nephrology, ATMP, Advanced Therapy Medicinal Product, IRDiRC, International Rare Diseases Research Consortium, RD Partnership, clinical research, diagnosis, diagnostics, orphan drugs, orphan medicinal products, rare diseases, therapies
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Open to legal entities established in EU Member States and countries associated to Horizon Europe (including EEA/EFTA countries, and other associated third countries). Action type: HORIZON-COFUND HORIZON Programme Cofund Actions. Additional conditions: "> General conditions 1. Admissibility Conditions, proposal page limit and layout Admissibility conditions are described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes. Proposal page limits and layout are described in Part B of the Application Form available in the Submission System. 2. Eligible Countries Eligible countries are described in Annex B of the Work Programme General Annexes. A number of non-EU/non-Associated Countries that are not automatically eligible... See the official call documentation on the F&T Portal for full eligibility criteria and participation rules. Confirm the full requirements in the official notice before applying.
The published deadline was September 15, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
European Partnership on Rare Diseases (ERDERA) (Phase 2) is funded by European Commission — Horizon Europe. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Reinforcing EU autonomous access to space through EU-based spaceports is sponsored by European Commission — Horizon Europe. Expected Outcome: Project results are expected to contribute to all of the following outcomes: Reinforcing EU strategic autonomy by reducing non-EU dependencies for accessing space; Providing an EU access to space necessary for EU space missions through state of the art and innovative solutions; Diversifying the access to space providers in the EU; Contributing to expand commercial access to space offers and services in the EU; Reinforcing Access to Space to ensure that Europe maintains and improve autonomous, reliable and cost-effective access to space. Scope: The EU needs to improve the resilience of its access to space for the implementation of EU space programme. New entrants will contribute to this endeavour. Projects are expected to support EU launch service providers to set up launch pad(s) in the EU territory enabling to perform EU launch services. Projects are expected to contribute to the development of necessary ground facilities to conduct launch services from the EU territory; e.g. launch integration, storage and operation facilities, launch pad and complex, control command facility, payload processing and integration facilities, tracking means, safety means, propellant storage... EU launch service provider(s) are expected to be part of the project consortium and be the ultimate users of the resulting facilities making use of EU launch vehicles for providing EU launch services. Proposals under this topic should explore synergies and be complementary to past actions related to ground segment for launch services, in particular the topics: HORIZON-CL4-2023-SPACE-01-23 and HORIZON-CL4-2025-02-SPACE-11. All the activities should be complementary with national and ESA on-going or future activities, in particular those decided at the ESA council Ministerial Meeting in November 2025. In this topic, the integration of the gender dimension (sex and gender analysis) in research and innovation content should be addressed only if relevant in relation to the objectives of the research effort. Technology Readiness Level - Technology readiness level expected from completed projects Activities are expected to achieve TRL 8 by the end of the project. The reference TRL definition is the ISO 16290:2013 applicable to the space sector. Programme areas: Horizon Europe (HORIZON), Global Challenges and European Industrial Competitiveness, Digital, Industry and Space
Space critical Equipment for EU non-dependence – Space Refuelling Interface is sponsored by European Commission — Horizon Europe. Expected Outcome: Project results are expected to contribute to all of the following expected outcomes: Reinforcing EU strategic autonomy by reducing non-EU dependencies on critical space Equipment and related technologies across their entire supply chain; Providing unrestricted access to critical space Equipment and related technologies relevant for EU space missions and pilots (e.g. In-Orbit Space Operations); Developing or regaining capacity to operate independently in space by developing resilient space Equipment and related technologies supply chains, relying on EU supply chains and/or trustable and reliable supply chains not affected by non-EU export restrictions; Enhancing competitiveness by developing products and capabilities reaching equivalent or superior performance level than those from outside the EU and compete at worldwide level. Scope: Unrestricted access to state-of-art space equipment and related technologies is a pre-requisite for the EU space industry responding to EU space missions. However, especially for some families of equipment, the available solutions in EU do not meet the current high-performance space requirements. Currently, alternative products sourced from outside EU, are either affected by non-EU export control, that limits its use, or present challenges in terms of trustable supply chains for the implementation of EU space missions with a security dimension. Within the frame of this topic, it is expected to finance and implement a development project aiming at maturing critical equipment with the final goal of lowering the dependency from outside EU. This will be done by establishing a long-term sustainable supply chain for supporting EU strategic autonomy in the space sector. The selection of the supply chains shall reflect this objective. Therefore, the supply chain shall preferably be built fully based in EU and when this can only be achieved partially, services procured from outside EU shall nevertheless ensure that the overall supply chain will remain trustable and not affected by non-EU export control. The latest scenario is subject to the approval of the granting authority (i.e. DG-DEFIS and HaDEA). The space equipment and related technologies relevant for this topic represent a direct implementation of the EU Observatory of Critical Technologies (OCT) Technology Roadmap, named Robotics Manipulators for Space Applications: Space Refuelling Interface . Further details will be provided at the latest at the opening of the Call, in a Guidance document published on the Funding & Tenders Portal. Space is a low volume market affected by a dynamic industrial landscape compared to the terrestrial market therefore, technological spin in and/or bilateral collaborations should be enhanced between European non-space and space industries. Furthermore, proposed activities should be complementary to relevant national or other activities at EU level. Complementary activities should be clearly identified, described and the proposal should report how the complementarity is ensured. To achieve the non-dependence objective, applicants are expected to include a dedicated proposal’s paragraph covering: The description of the technology and/or technology processes used for developing the equipment and high-level breakdown of the supply chain to be used. Applicants should demonstrate that the supply chain and final product are free of any legal export restrictions or limitations, such as those established in the International Traffic in Arms Regulations (ITAR) or equivalent instruments applicable in other non-EU jurisdictions. Applicants shall also report, in a dedicated subsection, if and which part of the supply chain is affected by non-EU export controls such as the Export Administration regulation (EAR) i.e. EAR99. The description of the suitable technology development process that has been identified and set up within the consortium for avoiding export restrictions of non-EU states and assess vulnerab Programme areas: Horizon Europe (HORIZON), Global Challenges and European Industrial Competitiveness, Digital, Industry and Space, Space, including Earth Observation
IA Resilience call reinforcing Europe's strenght in health is sponsored by European Commission — Horizon Europe. Expected Outcome: the proposals under this call are expected to address one or more of the following subjects : • Enhanced personalized monitoring, care and treatments, focusing on the development of highly customized healthcare solutions, including the required research and diagnostic tools, tailored to individual needs, covering various scenarios such as chronic disease management, physiotherapy, precision diagnosis, personalized medicine/treatment, pre- and postoperative care, and daily assistance in homes and common spaces. It also targets effective management of chronic diseases and elderly care through personalized monitoring and interventions facilitated by advanced sensor technologies and edge-to-cloud solutions. This includes the development and integration of solutions for Hospitalization at Home, enabling patients to receive complex, remotely supervised care using intelligent medical devices capable of sensing, analysing, and transmitting real-time data. This requires a continuum, from in-hospital diagnostics to robust, long-term patient support at home via AI-driven care pathways and hospitalization at home. • Prevention and treatment of diseases, allowing the improved scientific understanding, early detection and proactive prevention of diseases through scientific research, continuous monitoring, predictive analytics, and timely alerts, possibly powered by AI algorithms. This preventive approach enables early intervention and significantly reduces risks associated with many illnesses such as viral infections (e.g. epi- and pan demics), cardiovascular diseases, diabetes complications affecting the health of the young and old. • Efficient, scalable, and cost-effective healthcare, demonstrating how ECS-based technologies can streamline clinical workflows, reduce administrative burdens, and improve resource allocation in healthcare systems. This includes automation and intelligent operations management across clinical, diagnostic, and homecare settings, ultimately improving cost-effectiveness and scalability. • Secure and compliant healthcare continuum, including solutions that ensure robust data protection and regulatory compliance (e.g. GDPR), particularly in handling sensitive health data. Projects should adopt privacy-by-design principles and implement secure data handling architectures using localized edge computing, encryption, authentication, and anonymization strategies within both clinical and assisted living environments. • Seamless interoperability across devices, systems, and platforms, addressing the integration of heterogeneous systems across the edge-to-cloud continuum. Solutions should rely on open standards and modular architectures to ensure interoperability, flexibility, and adaptability across various healthcare settings and use cases, fostering a unified European health-tech ecosystem. Programme areas: Horizon Europe (HORIZON), Global Challenges and European Industrial Competitiveness, Digital, Industry and Space
The EU's last major Horizon Europe work programme puts €14B on the table through 2027. A strategic breakdown of budgets, deadlines, eligibility, and how US-based teams can compete.
Read articleEUR 307M in Horizon Europe AI calls closed April 15, 2026. US researchers can participate — but the rules are specific. Here is how to navigate them.
Read articleThe EU committed €900 million to lure researchers with relocation grants worth up to €2 million each. France placed 41 of 46 recruits from the US. Here is what the global talent war means for American research institutions and grant seekers.
Read article